Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
出版年份 2021 全文链接
标题
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
作者
关键词
-
出版物
JAMA Neurology
Volume 78, Issue 5, Pages 558
出版商
American Medical Association (AMA)
发表日期
2021-03-29
DOI
10.1001/jamaneurol.2021.0405
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Advances in oral immunomodulating therapies in relapsing multiple sclerosis
- (2020) Tobias Derfuss et al. LANCET NEUROLOGY
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
- (2019) J. William L. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis
- (2019) Stacie Hudgens et al. VALUE IN HEALTH
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
- (2019) Daniel Ontaneda et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Multiple sclerosis
- (2018) Alan J Thompson et al. LANCET
- Unknown
- (2018) STATISTICS IN MEDICINE
- Unknown
- (2018) EUROPEAN JOURNAL OF NEUROLOGY
- Fatigue in multiple sclerosis – Insights into evaluation and management
- (2017) Samar S. Ayache et al. NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
- (2016) Daniele D’Ambrosio et al. Therapeutic Advances in Chronic Disease
- Unknown
- (2016) ANNALS OF NEUROLOGY
- Unknown
- (2016) BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice
- (2015) A Pichler et al. Multiple Sclerosis Journal
- Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
- (2015) E.-W. Radue et al. NEUROLOGY
- Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation
- (2015) Moussa A. Chalah et al. Frontiers in Cellular Neuroscience
- Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice
- (2015) A Pichler et al. Multiple Sclerosis Journal
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator
- (2014) Andreas Krause et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
- (2013) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
- (2011) L. Piali et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature
- (2010) J. Chun et al. PHARMACOLOGICAL REVIEWS
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
- (2009) M. Hutchinson et al. JOURNAL OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now